drugset / Trial / NCT03672253
CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma
Phase 1
Unknown
20 enrolled
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, single-center, phase 1 study, to determine the safety and efficacy of autologous reinfusion of CAR-T cells targeting BCMA in the treatment of refractory/relapsed multiple myeloma (r/r MM) who get recurrence and progression after previous CAR-T cell therapy.
Timeline
- Start
- 2018-07-26
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T Re-treatment | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | CAR-T Re-treatment | Cell therapy | 2e+06 cells/kg | Intravenous |